Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
182
resultados
Última actualización
24/06/2025 [06:54:00]
Resultados 100 a 125 de 182
Resumen de: CN120132005A
本发明提供了一种具有抗菌和成像功能的钛酸钡/铋@聚吡咯纳米材料及其制备方法和应用。包括：S1.用水热法制备钛酸钡；S2.在钛酸钡纳米颗粒表面负载铋单质，构建钛酸钡/铋异质结；S3.在冰水浴下，将钛酸钡/铋异质结与预氧化的吡咯单体复合，制成钛酸钡/铋@聚吡咯纳米材料。本发明制备的钛酸钡/铋@聚吡咯纳米材料具有良好的生物相容性，优异的抗菌和成像性能，可用于创面或骨缺损修复等领域，可实现非侵入性、高效性和可控性抗菌，并可用于实时监测。
Resumen de: CN120131587A
本发明涉及阿霉素脂质体纳米药物的制备方法与应用领域，具体涉及一种地高辛为第五组分的可离子化阿霉素脂质体纳米药物的制备方法及其应用，利用可离子化脂质递送载体在肿瘤组织的酸性微环境作用下的质子化作用(具有叔胺结构的哌嗪在酸性条件下质子化形成阳离子)，与质子化的DOX发生排斥，实现快速、高效释放DOX，降低DOX@D‑LNP的毒副作用；利用具有心血管保护作用的药物DIG降低DOX介导的心脏毒性；同时利用DIG的抗肿瘤作用，提高DOX@D‑LNP的抗肿瘤效果。
Resumen de: CN120131584A
本发明公开了一种纳米药物及其制备方法与应用，涉及生物医药技术领域。本发明的纳米药物包括纳米颗粒和包裹于纳米颗粒中的活性药物；所述纳米颗粒包括载体和修饰于载体表面的靶向肽；所述活性药物为疏水性BCL‑2蛋白抑制剂；所述载体包括甲氧基聚乙二醇聚乳酸‑羟基乙酸共聚物；所述靶向肽包括cRGD肽。本发明的纳米药物基于活化血小板在肿瘤转移中的重要作用，采用cRGD肽修饰的载体靶向递送ABT‑737，特异性诱导活化血小板的凋亡，降低对静息血小板及正常组织的影响，药物的毒副作用降低，显著抑制黑色素瘤肺转移，增强PD‑1抗体的抗转移疗效；本发明的纳米药物基于血小板在多种肿瘤转移中的支持作用，可进一步拓展至黑色素瘤外的其他癌症类型晚期转移的治疗。
Resumen de: CN120131586A
本发明公开了一种光磁可视化生物杂化纳米体系及其制备方法和应用，所述光磁可视化生物杂化纳米体系包括血小板膜以及包裹在所述血小板膜内的负载氯沙坦的单宁酸锰络合物；本发明光磁可视化生物杂化纳米体系能够促进药物和免疫细胞的深层渗透性，并利用血小板膜的生物趋向性实现肿瘤靶向治疗，此外，还能够通过荧光成像和磁成像双重成像模式为精准靶向治疗提供可视化跟踪。
Resumen de: AU2023369585A1
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
Resumen de: CN120131653A
本发明公开了谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合、纳米颗粒递送系统及其应用，属于医药领域。本发明证明SLC7A11在肺腺癌中显著过表达，并与不良临床预后相关；通过实验发现谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合在中高SLC7A11表达细胞中表现出增强肺腺癌治疗效果，同时在低表达细胞中也能达到与SLC7A11过表达条件下葡萄糖剥夺相当的效果。为了优化递送方式并最小化全身毒性，本发明还制备了一种双细胞膜包被双药的纳米颗粒递送系统，该系统表现出增强肿瘤靶向和药物可控释放能力，有效解决了肿瘤中SLC7A11表达差异(异质性)问题，并在临床前模型中展示出显著的抗肿瘤效果，为肺腺癌的治疗提供了一种有前景的治疗方法。
Resumen de: CN120131947A
本发明公开了一种多酚包覆的金属氧化物纳米颗粒及其制备方法与应用，所述的纳米颗粒包括掺杂或不掺杂其他金属的金属氧化物内核和多酚类化合物壳层，本发明所述的材料具有作为多种医学影像造影剂的潜力，同时兼具清除活性氧以减少氧化应激的能力，作为诊疗一体化体系的应用潜力较大，此外，本发明的纳米颗粒的制备方法简单，生产成本低等。
Resumen de: CN120131919A
本发明涉及医用制剂技术领域，具体公开了一种硒基抗绝经后骨质疏松药物及其制备方法和应用，包括：主活性成分，为纳米硒‑植物雌激素复合物，由硒代蛋氨酸与大豆异黄酮通过共价偶联形成，其粒径为50‑200nm，硒元素质量占比为复合物的5％‑30％；辅助活性成分，为胶原肽‑钙螯合物，由海洋胶原肽与柠檬酸钙通过螯合反应制备，钙元素与胶原肽的质量比为1:3‑1:5；靶向递送载体，为叶酸修饰的壳聚糖纳米粒，负载所述主活性成分与辅助活性成分；辅料，包括崩解剂、润滑剂及pH敏感型肠溶包衣材料；本发明通过主活性成分纳米硒‑植物雌激素复合物与辅助活性成分胶原肽‑钙螯合物的协同作用，能够同时促进骨形成与抑制骨吸收，实现了双功能治疗。
Resumen de: CN120131585A
本发明涉及医药技术领域，尤其涉及一种新型纳米颗粒递药系统的制备方法及应用；包括以下步骤：A、将活化后的牛血清白蛋白加入到孔板中，再加入2‑吗啉乙磺酸缓冲溶液，在振荡条件下加入异槲皮苷溶液反应，反应后经洗涤得到BSA@ISO；B、将RVG29多肽溶在PBS中，加入步骤A中BSA@ISO溶液，搅拌反应后，经透析、离心得到BSA@ISO‑RVG29；C、向Ti2C中加入1‑(3‑二甲氨基丙基)‑3‑乙基碳二亚胺盐酸盐，接着加入N‑羟基琥珀酰亚胺，反应后加入步骤B中的BSA@ISO‑RVG29反应，反应后经洗涤得到Ti2C‑BSA@ISO‑RVG29。在牛血清白蛋白包裹疏水药物异槲皮苷(ISO)，并接枝RVG29靶向肽，之后装载在具有强自由基清除能力的Ti2C纳米酶上，成功制备了用于缺血性卒中治疗的纳米制剂。
Resumen de: US2025186357A1
The present application relates to ionizable lipids that include ester functional groups. The present application further relates to compositions and uses thereof for the delivery of agents such as nucleic acids and drugs.
Resumen de: WO2025121735A1
The present invention relates to a nano-platform comprising core-shell structured upconversion nanoparticles, a composition comprising same, and a treatment method, the nano-platform comprising: a core formed of NaYF4:Yb, Tm through single-step synthesis; and a shell, which encompasses the core and is formed of NaYF4:Nd.
Resumen de: US2025186343A1
An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.
Resumen de: US2025186390A1
Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2m/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.
Resumen de: US2025186609A1
The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement factor H (CFH). Modulating the activity of infectious organisms such as viral influenza A, B, C, SARS-CoV1, 2, and cancer/tumor cells such as lung, breast and skin cancers. The compositions comprise a particle, comprising a molecule represented by the following structural formula:P-L-G,wherein P is a biocompatible polymer scaffold comprising at least one biocompatible polymer defined herein, G is a polysialic acid (PSA) comprising from 5 to 200 repeat units of sialic acid; and L is a covalent linker, or a pharmaceutically acceptable salt thereof.
Resumen de: US2025186608A1
Detonation nanodiamond nanocarrier platforms to transport quaternary oxime antidotes into the central nervous system have been developed. The nanodiamond-based AChE reactivators contain an organophosphorus poisoning antidote (e.g., a 4-hydroximinopyridinium moiety) bound to a biocompatible linker covalently attached to the nanodiamonds. These functionalized nanodiamonds successfully cross the layer of Madin-Darby Canine Kidney (MDCK) cells, the epithelial cell surrogate BBB model, and demonstrate a measurable dose-independent in vitro reactivation capacity towards human AChE inhibited by toxic organophosphorus compounds.
Resumen de: US2025186360A1
The present invention provides a composition comprising liquid-liquid phase separation (LLPS)-based compartments comprising a cationic peptide and an anionic polymer, variations and modifications thereof, methods for preparation of the LLPS-based compartments, and uses thereof for delivery or for controlling entrapping and releasing of a payload.
Resumen de: US2025186607A1
A method for functionalizing plant viral nanoparticles (VNPs) includes selecting a plant VNP. Additionally, a metal ion and a phenolic compound that form a metal-phenolic network (MPN), and at least one functional component that adheres to the MPN are also selected. A nanohybrid structure is synthesized from a solution of the selected metal, the selected phenolic compound and the selected functional component such that the synthesized nanohybrid structure has an MPN coating encapsulating the plant VNP with the functional component being embedded in the MPN coating.
Resumen de: US2025186524A1
A method of preparing a carbon quantum dots (CD) and Moringa oleifera silver nanoparticle (CD-MOE-AgNP) composition includes providing a Moringa oleifera extract, combining the Moringa oleifera extract with silver nitrate to provide silver nanoparticles, and combining the silver nanoparticles with the carbon quantum dots (CD) to provide the CD-MOE-AgNP composition. In an embodiment, combining the carbon quantum dots (CD) with the Moringa oleifera silver nanoparticle (CD-MOE-AgNP) composition can include ultra-sonification of the carbon quantum dots (CD) with the Moringa oleifera silver nanoparticles.
Resumen de: US2025188013A1
The present application provides a novel lipid compound, a lipid nanoparticle comprising the same, and use thereof in targeted delivery of a drug. Specifically, the present application provides a compound of Formula Ior a pharmaceutically acceptable salt, a prodrug, or a stereoisomer thereof. Furthermore, the present application provides a lipid nanoparticle comprising the compound of Formula I or a pharmaceutically acceptable salt, a prodrug, or a stereoisomer thereof; still further, the lipid nanoparticle may further comprise a cationic lipid; yet still further, the lipid nanoparticle may further comprise a helper lipid. A composition comprising the above compound or a pharmaceutically acceptable salt, a prodrug, or a stereoisomer thereof, or the lipid nanoparticle can achieve the organ-targeted delivery of a therapeutic/prophylactic agent.
Resumen de: US2025188020A1
Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2025188016A1
Compounds are provided having the following Formula (I):or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3a, R3b, R3c, R3d, L1, L2, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2025188025A1
A nanosized complex includes a nucleic acid and a compound comprising formula (I):wherein R1 is an alkylamino group or a group containing at least one aromatic group;R2 and R3 are independently an aliphatic group or hydrophobic group;R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R4 and R5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein;a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.
Resumen de: WO2025122024A1
The present invention discloses the use of local chemotherapy after laser hyperthermia treatment of a brain tumour. A pharmaceutical composition for local postoperative chemotherapy comprises a chemotherapy drug, in particular doxorubicin, loaded into nanoparticles obtained from a copolymer of amino acids that are natural metabolites in the brain.
Resumen de: US2025186635A1
The present disclosure relates to a plurality of globular nanostructures. Each nanostructure comprises a central part comprising a polymer framework of monomer residues according to {(OR1)(OR2)PO}2—(C){(CH2)mSi(OR3)3}{(CH2)mSi(OR3)3}, wherein each R1 and R2 is independently selected from the group consisting of a negative charge and H; each R3 is independently selected from the group consisting of a negative charge, H and a covalent bond to the polymeric framework; wherein at least 3 R3 are bonds to the polymeric framework; and m is an integer between 1 and 5; and, wherein the central parts of the nanostructures have a volume average hydrodynamic diameter of 10 nm to 90 nm; and an anchoring layer surrounding the central part, wherein the anchoring layer comprises a polymer of monomer residues according to (RO)3Si(CH2)nSi(OR)3, wherein each R is independently selected from the group consisting of a negative charge, H and a covalent bond, wherein at least two R are independently selected from the group consisting of a covalent bond to a monomer residue of the central part and a covalent bond to a monomer residue of the anchoring layer; wherein represents a covalent bond; n is 1 or 2; and wherein the anchoring layer has a thickness of 1-5 nm. The present disclosure also relates to a method for producing such nanostructures as well as the use of the nanostructures and to pharmaceutical compositions comprising such nanostructures.
Nº publicación: US2025186402A1 12/06/2025
Solicitante:
EAGLE PHARMACEUTICALS INC [US]
Eagle Pharmaceuticals, Inc
Resumen de: US2025186402A1
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
BOPI
Sede Electrónica
